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Summary
Background Chemical haptens induce both contact and allergic respiratory disease with
dendritic cells (DCs) controlling and directing immune responses in vivo. Contact and
respiratory haptens may promote differential cytokine production yet distinguishing these
effects in vitro remains difficult due to human donor variability.
ObjectiveWe sought to determine the effect of atopic status on the ability of DC to respond to
contact and respiratory sensitizer treatment in vitro as DC from atopic donors are believed to
promote Th2-type responses.
Methods Enriched DC from control or atopic donors were treated for 4 h with levels of the
contact sensitizer 2,4-dinitrochlorobenzene (DNCB) or the respiratory sensitizer trimellitic
anhydride (TMA) that did not reduce cell viability. A sensitive intracellular detection
technique was used to measure cytokine production, while T cell responses were assessed in a
mixed leucocyte reaction.
Results DC from control, non-atopic, donors produced cytokines differentially in response to
sensitizer treatment; DNCB treatment significantly increased the production of Th1 cytokines
IL-12 and IFN-g while TMA induced the production of IL-13. Control donor DC treated with
TMA stimulated less in a mixed leucocyte reaction than untreated cells with any response
reduced further by blocking IL-13 in culture. However, DC from atopic donors showed no
significant alteration in either cytokine production or T cell stimulatory capacity after
sensitizer treatment.
Conclusion Haptens modulate DC by changing the production of cytokines that may play a
role in T cell stimulation and subsequent polarization of the immune response. DC from atopic
donors were unresponsive to chemical sensitizer treatment, and may be deficient in inducing
divergent T cell responses.
Keywords atopy, contact hypersensitivity, DNCB, TMA
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Introduction
Contact hypersensitivity (CHS), a delayed-type allergic
response, can be elicited by chemical haptens. Haptens
covalently bound to protein are taken up by Langerhans
cells, which deliver antigen via afferent lymphatics to
local lymph nodes [1]. Dendritic cells (DCs) and their
responses to chemical sensitizers have been studied in
order to develop in vitro tests for identification of chemi-
cal contact sensitizers. Monocyte-derived DC treated in
culture with contact sensitizers may increase the produc-
tion of IL-1-b [2] and are reported to up-regulate the
expression of maturation markers such as CD54, CD86,
HLA-DR and CCR7 [3–5]. Recent advances demonstrate
that contact sensitizers activate specific signal transduc-
tion systems such as p38 MAP and ERK kinases [6] and
affect the redox state of the cell [7].
DC responses to haptens which cause respiratory sensi-
tization are less well studied. It has recently been sug-
gested that contact and respiratory sensitizers could be
differentiated through the production of hapten-specific
IgE. In rodent models serum IgE is increased after topical
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treatment with the model respiratory sensitizer trimellitic
anhydride (TMA) but not the model contact sensitizer
2,4-dinitrochlorobenzene (DNCB) [8, 9]. However, in hu-
mans the production of specific IgE to some respiratory
haptens has not been fully confirmed, for example, iso-
cyanate-specific IgE may be found in only a proportion of
symptomatic individuals [10]. Allergic responses can also
be defined according to cytokine profiles: contact sensi-
tivity, a predominantly cell-mediated immune response, is
associated with the production of Th1 cytokines; respira-
tory allergy has the converse Th2 cytokine profile. Cyto-
kine secretion profiles in lymph nodes of sensitized
mice show this differentiation with topical treatment with
TMA inducing production of Th2 cytokines IL-10 and
mitogen-induced IL-4 and DNCB sensitization leading to
high IFN-g production [11]. Subsequent studies have
further validated these findings, extending the detection
of cytokines to include IL-2, IL-5 and IL-13, all of which
fit the expected Th1/Th2 profiles [12–14]. As DCs have the
potential to polarize T cell responses through their own
cytokine production, hapten presenting Langerhans cells
may influence both helper and cyto-toxic T cell polariza-
tion in the context of chemical sensitization.
Human donor variability remains a real problem when
studying the effect of chemical sensitizers in vitro [15] and
responses of DC from reactive individuals are yet to be
fully defined. Atopy, the predisposition to develop im-
mediate-type hypersensitivity reactions, may contribute
to variability seen in DC responses to chemical allergens
and may influence cytokine production. The inflamma-
tory process involved in immediate-type allergic disease
centres around Th2 lymphocytes secreting cytokines such
as IL-4, IL-5 and IL-13 [16–18]. The effect of atopy on an
individual’s ability to react to contact sensitizers is un-
clear. Atopic individuals can be sensitized with chemical
haptens [19]. However, CHS responses may be impaired in
these individuals [20]. These impaired responses may
extend to in vitro work with peripheral blood mono-
nuclear cells (PBMCs) from atopic donors being largely
non-responsive to the contact allergen nickel (Ni1)
compared with PBMCs from non-atopic individuals [21].
Changes in DC induced during prolonged separation
procedures or generation of DC from monocyte precursors
using cytokine treatments, may influence the character-
istics of DC. Cyto-toxicity of chemical sensitizers may also
present a problem when interpreting changes in DC after
sensitizer treatment in vitro; apparent alterations in phe-
notype may reflect preferential loss of some cells rather
than changed antigen expression on surviving cells. We
aimed to treat DC enriched from peripheral blood of both
atopic and non-atopic donors with the model contact
sensitizer DNCB and the model respiratory sensitizer
TMA for short time periods using doses that were not
overtly toxic. Intracellular cytokine production by these
cells was investigated along with their ability to induce
a primary T cell stimulatory response. We have shown
that the sensitizers may modulate immune responses
through cytokine production in DC from control but not
from atopic donors.
Methods
Antibodies
Mouse IgG1 clone x40, IgG2a G155, IgG2b MPC-II, IL-12
C115.5, blocking IL-13 JES10-5A2, Blocking IL-12 C86,
HLA-DR l243, b7 FIB504 (BD Biosciences, Oxford, UK).
IL-10 JES39D7, IFN-g D9D10, TLR2 TL2.3, TLR4 HTA125,
CD40 LOB7/6, CD86 BU63, CD54, 15.2 (Serotec, Oxford,
UK). IL-4 3007 (R&D systems, Abingdon, UK), IL-13
32007.111 (Oxford Biotechnologies, Oxford, UK), HLA-
ABC W6/32 (eBioscience, San Diego, CA, USA), CD11c
KB90 (Dakocytomation, Ely, UK), CD83, HB15e (Ancell,
Nottingham, UK), DC-SIGN, 120507 (R & D systems).
Reagents and chemicals
Monensin (Sigma, Poole, UK) was made up in ethanol to a
stock solution of 3mM. Metrizamide (Sigma) was used at
14.5% (w/v) in RPMI Dutch modified (Sigma) with 10%
FCS. DNCB (Sigma) was used as a stock solution of 5mM
dissolved in ethanol and further diluted in sterile PBS
(Sigma). TMA was used as a stock solution of 5mM
dissolved in acetone and further diluted in PBS. Final
concentration of ethanol or acetone in test solution never
exceeded 0.01%. FACS buffer was PBS with added FCS
(2%), EDTA (1mM) and sodium azide (0.2%).
Subjects
To determine atopic status, all donors were skin prick
tested to a panel of common aeroallergens: Dermatopha-
goids pteronyssinus, dog hair, cat fur, feather mixture,
grass pollen, Cladosporium herbarum,Alterneria alternata,
Candida albicans and Aspergillus fumigatus (ALK-
Abello, Horsholm, Denmark). Atopic donors were defined
by a positive skin prick test reaction (43mm weal) to
two or more aeroallergens or as subjects exhibiting a
positive reaction to one skin-test allergen in conjunction
with an atopic family history. Atopic donors displayed no
symptoms relating to their atopy at the time of donating
blood and had not used antihistamines for 24 h preceding
the study. Both control and atopic subjects were non-
smokers or had not smoked for at least 1 year before the
study. Control donors (two female, 10 male) had a mean
age of 32 (range: 21–57). Atopic donors (five female,
seven male) had a mean of age 38 (range: 22–67).
Informed consent was received from all subjects and the
local ethics committee approved the protocol.
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Enrichment of dendritic cells
Low-density cells (LDCs) enriched for DC were isolated
from the non-adherent fraction of PBMCs cultured over-
night (37 1C, 5% CO2) and centrifuged over either metri-
zamide gradient (14.5% w/v) [22] or Nycoprep 1.068
(Nycodenz) gradient (Axis-Shield, Kimbolton, UK) [23].
Cell analysis showed DC isolation with either gradient to
be comparable with the isolated population highly en-
riched for DC with high surface expression of HLA-DR,
CD11c, CD83 and CD86. This method of DC enrichment
consistently gave a yield of 5–7% of the total number of
PBMCs isolated for all donors.
Cell viability
The cyto-toxicity of both sensitizers was assessed at
varying concentration by the inclusion of the viability
probe Viaprobe (Becton Dickinson, Oxford, UK). Cells
positive for Viaprobe incorporation (expressed as a per-
centage) were determined by the position of a region gate
placed on the histogram of LDC without Viaprobe using
WINLIST software (Verity Software House, Topsham, ME).
Dendritic cell treatment
Cells at a concentration range of 5–10105/mL cells in
Dutch-modified RPMI medium plus 10% were treated with
5 mM DNCB or TMA for 4 h in a humidified 5% CO2
incubator. Final concentration of solvent in test sample
never exceeded 0.01%. Dead cells as a result of sensitizer
treatment never exceeded 5% above that observed in
untreated cells demonstrated using Viaprobe.
Intracellular cytokine detection
LDC at a concentration of 3–5105 were incubated in
Dutch modified RPMI plus 10% FCS with or without added
sensitizer for 4 h at 37 1C in the presence of 3 mM monensin
to retain any newly synthesized protein. A paired sample
of LDC was also incubated for 4 h in medium alone. Cells
were washed and re-suspended in 100 mL of FACS buffer
and 50 mL Leucoperm reagent A (Serotec) left at room
temperature on a cell shaker for 15min. FACS buffer was
added and cells centrifuged for 5min at 500 g. Cells
were re-suspended in 100 mL Leucoperm reagent B (Ser-
otec). Directly conjugated anti-cytokine monoclonal anti-
body (5 mL) was added and left for 30min at room
temperature on a cell shaker. LDC were again washed in
FACS buffer and re-suspended in 100 mL FACS buffer and
fixed with 1% paraformaldehyde.
Phenotype
LDC treated in the presence of sensitizer or irritant for 4 h
were analysed for cell markers by flow cytometry. Cells
were washed and incubated in FACS buffer in the presence
of conjugated antibodies for 30min at room temperature.
Cells were washed further in FACS buffer and fixed with
1% formaldehyde.
Flow cytometry acquisition and analysis
Samples were acquired on a FACScalibur flow cytometer
using CELL QUEST software (Becton Dickinson) with
1104cells acquired per tube. Forward and side scatter
gating excluded dead cells and contaminating lympho-
cytes. List mode data was analysed using WINLIST soft-
ware. Antibody staining was quantified by subtracting
normalized cumulative control histograms from similar
test histograms using the super enhanced DMAX method
[24, 25]. This sensitive method allows positive events to be
identified even when control and test histograms overlap.
From subtraction, values are generated for the number of
positive cells as a percentage and the intensity of staining
as a ratio of the median value of positive events in the test
histogram to the median value of the control histogram.
For surface labelling, isotype control histograms were
subtracted from test histograms. For intracellular cytokine
analysis, histograms from cells incubated without monensin
(control) were subtracted from histograms representing cells
incubated in the presence of monensin (test histogram).
Subtracting histograms of cells that have been stimulated
and stained in the same way ensures that there is minimal
difference in non-specific binding between test and control
samples. Comparisons are not made with an isotype
matched control antibody because the sensitive subtraction
technique may detect small differences between antibodies
unrelated to antigen specificity, for instance in different
levels of free fluorochrome. By subtracting no monensin
histograms from monensin histograms build-up of trapped
synthesized proteins is detected in a 4 h window. For this
method the control histogram does not act as a negative
control. Instead it is a reference point for cytokine produc-
tion. By reference to this value, cytokine production could
be measured as an increase of cytokine over the period of
culture. When a control histogram had more ‘positive’
events than the test histogram the subtraction was reversed
indicating a loss of pre-existing cytokine from cells and
shown as a negative number. This technique has been
validated in a recent publication from our laboratory [26].
Mixed leucocyte reactions
For assessment of T cell stimulation, enriched DC were
incubated with freshly isolated PBMCs from a different
donor. Triplicate cultures containing 2500–100000PBMCs/
well were set up in Terasaki plates. LDCs were added at a
concentration of 1000 per well to give a culture volume of
20 mL. Control wells contained PBMCs alone or PBMCs
and untreated DC. A positive control of PBMCs plus
c 2008 The Authors
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Concanavalin A (5 mg/mL) (Sigma) was also used. Inverted
Terasaki plates were cultured over 0.85% saline at 37 1C in
5% CO2 for 3 days. Wells were then pulsed with
3H
thymidine (1 mg/mL specific activity 37 kbq/mL) (Amer-
sham Bioscience, Amersham, UK) for 2 h, conditions
ensuring free availability of the precursor for the whole
culture period. Cells were harvested by blotting onto damp
filter paper and washed with saline, 5% trichloroacetic
acid for DNA precipitation and methanol to dry. When
fully air-dried, incorporation of 3H thymidine was assayed
by exposing filters for 4 h on a molecular dynamics
phosphor screen and imager. The counts were closely
correlated with scintillation counts although actual
counts obtained were lower [27]. Because replicate cul-
tures using multiple cell concentrations were performed in
each experiment, significant differences between treat-
ments in individual experiments were assessed using
ANOVA of the log transformed, normally distributed data.
Cytokine blocking of mixed leucocyte reactions
A separate Terasaki plate contained neutralizing anti-
cytokine antibodies (10 mg/mL) added to each test well
before 3-day incubation. Because the possibility of inter-
plate variability the direct effect of neutralizing antibody
was also confirmed in cultures with and without antibo-
dies set up on the same plate.
Results
Dose responses and viability assay for 2,4-
dinitrochlorobenzene and trimellitic anhydride treatment
Concentrations of chemical sensitizers that did not reduce
viability were selected to treat enriched DC. Grouped data
(n= 5) (Fig. 1) highlighted that DNCB was more cyto-toxic
in vitro compared with TMA following 24-h incubation
with DC. At both 10 and 20 mM both sensitizers signifi-
cantly increased the number of non-viable cells. As 5 mM
was deemed to be the highest non-toxic concentration in
this system we used this in all future experiments.
Dendritic cell from control but not atopic donors showed
polarized cytokine production in response to contact and
respiratory sensitizers
DC from control donors produced divergent cytokine
responses when treated with the two haptens for 4 h.
DNCB treatment significantly increased the percentage of
IL-12 and IFN-g containing cells (Fig. 2a) as well as their
respective positive intensity ratios (Fig. 2b). TMA treat-
ment of DC from this donor group induced significant
production of IL-13 as seen in the number of IL-13
containing cells (Fig. 2a). Atopic donor DC, on the other
hand, showed no reproducible responses to either DNCB or
TMA sensitizer treatment. Variable responses were seen
between different donors, and as a result, no significant
changes were observed in the number of cytokine con-
taining cells (Fig. 2a) or the associated positive intensity
ratios (Fig. 2b). Thus control DC mounted a polarized
cytokine response to the chemical sensitizer while atopic
DC did not differentiate the two chemical haptens in terms
of cytokine production.
Dendritic cell cytokine responses to both contact and
respiratory sensitizers may be affected by basal levels of
cytokine production in untreated cells
The basal levels of cytokine production in untreated DC
taken from control and atopic donors were investigated
(Fig. 3). We found no evidence that cytokine production in
the two donor groups differed in the untreated cells (data
not shown). However, levels of cytokines produced in
unstimulated DC had a bearing on cytokine production in
response to the chemical stimulus. When untreated DC
were producing high amounts of an individual cytokine
sensitizer treatment had minimal effect on cytokine pro-
duction; high detection of that cytokine was maintained
(Fig. 3a). DNCB, however, significantly reduced the detec-
tion of IL-13 in control donors. When the production of
individual cytokines was low or absent (negative after
subtraction), sensitizer treatment resulted in the up-
regulation of cytokines in a polarized manner (Fig. 3b).
This effect was best represented in control donors where
DNCB treatment significantly up-regulated the produc-
tion of IL-12, IFN-g and IL-4. TMA treatment markedly
up-regulated the production of IL-13 and IL-10 and, to
Fig. 1. Dose–response experiments. Unstimulated dendritic cell and
cells treated with increasing concentrations of 2,4-dinitrochlorobenzene
’ or trimellitic anhydride & for 24 h were quantified for cell death
through the incorporation of Viaprobe measured as mean percentage
positive cells compared with a non-labelled control (n=5)SEM.
Po 0.05, Po 0.01, Po 0.001 determined by paired Student’s t-test.
c 2008 The Authors
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some extent, IL-4 and IFN-g. A similar pattern was
observed in atopic donor DC, although responses were
not statistically significant due to high variability be-
tween donors. The data suggest that sensitizers induce
greater cytokine production in DC when cells are in a more
resting state and producing little cytokine.
2,4-Dinitrochlorobenzene but not trimellitic anhydride
sensitizer treatment affected surface phenotype of
dendritic cell taken from control and atopic donor
dendritic cell
Sensitizer treatment induced alterations to surface pheno-
type of DC in vitro were assessed. Minor changes in
phenotype were observed after 4-h hapten treatment but
significant alterations were observed for some markers.
Control donor DC (Fig. 4a) treated with DNCB had sig-
nificantly reduced surface expression of CD54 (Fig. 4b).
This effect was not seen in atopic donor DC (Fig. 4c)
although we did observe a significantly reduced surface
expression of HLA-A/B/C and HLA-DR in response to
DNCB treatment (Fig. 4d). There was no phenotypic
response to TMA in DC from either donor group.
Dendritic cell taken from control donors and treated with
trimellitic anhydride inhibited primary T cell proliferation
dependent on the T cell donor
The effects of sensitizer treatment on the ability of DC to
stimulate T cells was assessed. We included DC from either
control or atopic donors into a mixed leucocyte reaction
with responder PBMCs from a different donor. DNCB
treatment of DCs from control or atopic donors had no
effect on T cell proliferation compared with untreated cells
(Fig. 5). TMA-treated DC from control donors, however,
significantly reduced T cell stimulation when included in
Fig. 2. Intracellular cytokine production in dendritic cell (DC) from different donor groups stimulated with either the contact sensitizer 2,4-
dinitrochlorobenzene (DNCB) or the respiratory sensitizer trimellitic anhydride (TMA). Enriched DC from control (n=12) and atopic donor groups
(n= 12) were analysed for cytokine production when untreated’ and in response to 4 h DNCB (5 mM) or TMA (5mM)& chemical sensitizer treatment.
Intracellular cytokine was detected by incubating cells with the secretion inhibitor monensin. A paired cell sample was also treated for 4 h in the absence
of monensin. By subtracting control histograms (no monensin) from test histograms the accumulation of cytokine plus or minus the control can be
calculated. Results are presented as cytokine containing cells after subtraction (a) and their associated positive intensity ratios (b) MeanSEM.
Po 0.05 determined by paired Student’s t-test
c 2008 The Authors
Journal compilation c 2008 Blackwell Publishing Ltd, Clinical and Experimental Allergy, 38 : 1148–1159
1152 N. J. Holden et al
a mixed leucocyte reaction (MLR). Six out of ten indivi-
dual MLR experiments using TMA-treated control donor
DC resulted in a significant reduction in T cell responses.
Responses were independent of atopic status of the PBMC
donor. The inhibitory effect of TMA was not observed
when atopic donors DCs were included in an MLR, in 10
individual experiments. The data demonstrate that DCs
from control donors can reduce an allogeneic T cell
response when stimulated with TMA; atopic donor DCs
did not possess this property.
Interleukin-13 enhanced T cell stimulation to respiratory
but not contact sensitizers
Neutralizing antibody to IL-13 was added to a mixed
leucocyte reaction to determine whether the production
of IL-13 in response to chemical sensitizer treatment had
any functional effect on T cell stimulation. As previously
demonstrated, DNCB-treated DC induced comparable
T cell stimulation in an MLR compared with untreated DC
whereas TMA-treated DCs exhibited significantly lower
stimulatory capacity compared with untreated cells (Fig.
6a). The two plates were repeated in the presence of
neutralizing IL-13 antibody (Fig. 6b). When IL-13 was
blocked, T cell stimulation induced by DNCB-treated
DC was significantly higher than that seen with untreated
DC whereas TMA-treated cells exhibited a more signifi-
cant loss in stimulatory activity with the proliferation
induced similar to background PBMC proliferation. To
rule out plate-to-plate variability and to confirm that the
neutralizing antibody was acting on sensitizer-treated
cells, the effect of anti-IL-13 antibody was also confirmed
within the same Terasaki plate (Fig. 6c). Similar results
were observed in three out of five experiments. No
significant difference was seen in responses to untreated
cells in the presence of the neutralizing antibody.
Fig. 3. Intracellular cytokine responses can be split into two groups based on high or low cytokine production in unstimulated cells. Untreated dendritic
cell (DC)’, 2,4-dinitrochlorobenzene (DNCB) treated (5 mM) and trimellitic-anhydride-treated DC (5 mM)& incubated for 4 h were grouped depending
on starting cytokine levels. By subtracting control histograms (no monensin) from test histograms, the accumulation of cytokine plus or minus the
control can be calculated. Responses were grouped based on starting levels of cytokine production in unstimulated cells, with those that show high
positive responses (a) and those where unstimulated DC lost cytokine giving negative values after subtraction (b). Results are presented as
mean cytokine containing cells after subtractionSEM Po 0.05, Po 0.01, Po 0.001 determined by paired Student’s t-test.
c 2008 The Authors
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T cell stimulation down-regulated by trimellitic anhydride
can be restored through the neutralization of IL-12
We next assessed whether IL-12 production by DC in
response to TMA treatment had any functional effect on
the proliferation of T cells. IL-12 was blocked with a
neutralizing antibody in a mixed leucocyte reaction. DC
incubated with TMA induced significantly less stimula-
tion of T cells than control untreated cells (Fig. 7a). When
the plate was repeated in the presence of neutralizing
IL-12 antibody, TMA-treated DCs exhibited comparable
stimulatory activity with untreated cells. To rule out plate-
to-plate variability and to confirm that the antibody was
acting on sensitizer-treated cells the effect of anti-IL-12
antibody on sensitizer-treated cells was also confirmed
within the same Terasaki plate (Fig. 7c). This effect of anti-
IL-12 antibody was observed in three out of five experi-
ments. It was not seen in two experiments where TMA-
treated cells had a stimulatory capacity similar to that of
untreated cells. No difference was seen in responses to
untreated cells in the presence of the neutralizing antibody.
Discussion
We demonstrated that DC produced polarized cytokine
responses to contact and respiratory sensitizers in vitro.
This effect of sensitizer treatment was only observed in DC
isolated from control but not atopic donors. DC from
control donors up-regulated the production of Th1 cyto-
kines IL-12 and IFN-g in response to DNCB and up-
regulated the production of the Th2 cytokine, IL-13 in
response to TMA. This Th1/Th2 profile is in accordance
with both murine models [28] and in vitro studies [29].
The majority of published research concerning interac-
tions of chemical haptens with human DC has utilized
DC differentiated from monocytes or CD341 progenitors.
We chose to investigate cells that could be isolated simply
from human blood, required no long-term culture and had
Fig. 4. Surface phenotype of sensitizer treated dendritic cell (DC) isolated from control or atopic donors. Untreated’, 2,4-dinitrochlorobenzene (5 mM)
and trimellitic anhydride (5 mM) treated DC& incubated for 4 h from control (a) (n=9) or atopic donors (c) (n= 12) were labelled with antibody for
surface markers and analysed by flow cytometry. Results are expressed as mean positive intensity ratiosSEM for each marker after subtraction of an
isotype control antibody histogram. Representative histograms are shown for CD54 in control DC (b) and HLA-ABC and HLA-DR in atopic DC (d).
Shaded histogram represents isotype control, solid line histogram represents staining of untreated cells while dashed line histogram corresponds to
DNCB-treated DC. Po 0.05 determined by paired Student’s t-test.
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the distinctive phenotype and allo-stimulatory capabil-
ities of DC.
It is becoming increasingly apparent that changes to DC
phenotype may be heavily influenced by the degree of
cyto-toxicity of the hapten in vitro. Many reported posi-
tive responses have arisen through the treatment of DC
with very high/sub-toxic concentrations of haptens, and
although a number of groups have demonstrated changes
in DC phenotype using apparently non-toxic concentra-
tions it has been suggested that low levels of cyto-toxicity
in these systems may have not been detected [30]. We
have attempted to use only non-toxic concentrations of
chemical sensitizers with short incubation times to reduce
the likelihood of changes in DC function being attributa-
ble to chemical cyto-toxicity.
DC cytokine responses to chemical sensitizer treatment
were dependent on basal cytokine production in untreated
cells; more exaggerated cytokine responses to chemical
sensitizers were observed when un-stimulated DC pro-
duced little or no cytokine. This effect was best repre-
sented in control donor DC. DNCB treatment up-regulated
the production of the Th1 cytokines IL-12 and IFN-g along
with the Th2 cytokine IL-4, whereas TMA treatment up-
regulated the production of IL-13 and IL-10. Although
CHS has a predominantly Th1 cytokine profile, IL-4 may
be required for CHS induction in vivo [31]. It would be of
interest to see if this reactive cytokine profile, seen in a
number of control donors, was stable and reproducible
over a longer time point. Unfortunately, this was not
possible as the majority of donors only visited the clinic
on a single occasion. If the profile was stable differential
donor responses could be studied in more detail and the
mechanism of the response investigated further.
The production of IL-10 in response to respiratory
haptens may be fundamental in the progression of a Th2
response. Topical treatment with TMA rapidly up-regu-
lates the production of IL-10 in the epidermis of animals
[32] halting the migration of Langerhans cells and prob-
ably helping to induce a Th2 profile of disease. IL-10 also
promotes immunological tolerance to inhaled antigens
[33]. We have confirmed that TMA up-regulates the
production of IL-10 after short time incubation and this
Fig. 5. Stimulatory capacity of sensitizer-treated dendritic cell (DC) isolated from control and atopic donors determined in a mixed leucocyte reaction.
DC isolated from atopic or control donor groups were treated with 5 mM 2,4-dinitrochlorobenzene (DNCB) or 5mM trimellitic anhydride (TMA) for 4 h and
assessed for their stimulatory capacity in a mixed leucocyte reaction. DC (1000) were added to increasing numbers of allogeneic peripheral blood
mononuclear cells (PBMCs) (x-axis) in triplicate wells. Proliferation was assessed on day three by 3H thymidine incorporation (quantified by
densitometry) and results are the meanSEM. Included in individual plates were control wells containing PBMCs alone ’ and PBMCs with the
addition of untreated DC ., test wells contained PBMCs with sensitizer-treated DC . Each graph shows representative data for 10 individual
experiments carried out. Po 0.05 determined by ANOVA.
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Fig. 6. IL-13 blocking in a mixed leucocyte reaction. Dendritic cell (DC) isolated from control donors were treated with 2,4-dinitrochlorobenzene (5 mM)
or trimellitic anhydride (TMA) (5 mM) for 4 h and included in an MLR to determine T cell stimulation (a). One thousand DC were added to increasing
numbers of allogeneic PBMCs (x-axis) in triplicate wells. Proliferation was assessed on day three by 3H thymidine incorporation (quantified by
densitometry) and results are the meanSEM. (a) Control wells consisted of PBMCs alone’ and PBMCs with the addition of untreated DC., test wells
(dashed line) contained PBMCs with sensitizer-treated DC. These plates were repeated with the addition of 10mg/mL anti-IL-13 antibody to each well (b).
To confirm that anti-IL-13 antibody was acting on IL-13 released by sensitizer-treated DC and to rule out plate variability, the effect of anti-IL-13 antibody
on sensitizer-treated dendritic cells (DCs) was confirmed in the same plate (c) with the addition of sensitizer-treated DC& or sensitizer-treated DC plus
anti-IL-13 antibody (dashed line)  to responder PBMCs. Po 0.05, Po 0.01 determined by ANOVA.
Fig. 7. IL-12 blocking in a mixed leucocyte reaction. Dendritic cell (DC) isolated from control donor groups were treated with TMA (5 mM) for 4 h and
included in a mixed leucocyte reaction to determine T cell stimulation (a). One thousand DC were added to increasing numbers of allogeneic PBMCs
(x-axis) in triplicate wells. Proliferation was assessed on day three by 33H thymidine incorporation (quantified by densitometry) and results are the
meanSEM control wells consisted of peripheral blood mononuclear cells (PBMCs) alone’ and PBMCs with the addition of untreated DC., test wells
(dashed line) contained PBMCs with TMA-treated DC . This plate was repeated with the addition of 10mg/mL anti-IL-12 antibody to each well (b). To
confirm that anti-IL-12 antibody was acting on IL-12 released by sensitizer-treated DC and to rule out plate variability, the effect of anti-IL-12 antibody
on sensitizer-treated dendritic cells (DCs) was confirmed in the same plate (c) with the addition of TMA-treated DC& and TMA-treated DC plus anti-
IL-12 antibody  (dashed line) to responder PBMCs. Po 0.05 determined by ANOVA.
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may coincide with the induction of a Th2 response
through the production of IL-13. Toeback et al. [34]
demonstrated that DC treated in vitro with DNCB in the
presence of CD-40L-transfected J558 cells showed high
production of IL-12 compared with IL-10 whereas TMA-
treated cells produced higher amounts of IL-10. Using a
sensitive intracellular technique we have confirmed this
pattern of cytokine production in freshly isolated DC and
we suggest that chemical haptens alone can induce the
production of polarized cytokines by DC without the
requirement for CD-40 ligation. This early cytokine pro-
duction in the epidermis may affect acceleration and
direction of the immune responses.
No reproducible evidence was obtained to suggest that
DCs from atopic donors exhibited differential cytokine
production in response to chemical sensitizer treatment.
The question whether DC from atopic donors are prone
to promote Th2-type responses has not been clearly
answered, although a number of studies suggest this to
be the case [35, 36]. In this study, however, we found no
overall difference in ongoing cytokine production of
unstimulated DC isolated from control or atopic donors,
and no differential cytokine response from atopic donor
DC to the respiratory hapten TMA. A lack of uniformity of
DC cytokine responses in vitro may represent different
levels of atopic disease in our donor group. Different
cytokine patterns are observed within different forms of
atopic disease and levels of cytokines such as IFN-g may
correlate with atopic disease severity [37]. However, we
could not discern any pattern of cytokine production in
the DC in relation to patient history of allergic disease or
skin prick test results.
DC from control donors were less stimulatory to T cells
when treated with TMA in vitro thus indicating that these
DC may be able to induce tolerance. Any T cell response to
the respiratory sensitizer was dependent on IL-13 produc-
tion, a finding in keeping with recent reports suggesting
that immune responses developed to inhaled antigens are
dependent on production of IL-13 [38, 39]. We also
suggest that IL-13 may also have a regulatory affect on
Th1 immune responses as blockade of the cytokine had a
positive effect on T cell proliferation induced with DNCB-
treated DC. Whether IL-13 produced by DC acts directly on
T cells in the MLR is uncertain. T cells are not believed to
possess a functional IL-13 receptor [40], but may up-
regulate the Th2-associated transcription factor STAT6
[41] in response to the cytokine. One possibility is that
IL-13 has a synergistic effect on other Th2 or regulatory
cytokines such as IL-4 or IL-10, both of which we found to
be up-regulated along with IL-13 in response to TMA
treatment in vitro.
We found no difference in the phenotype of DC isolated
from atopic or control donors. The demonstration that DCs
from control donors down-regulate CD54 in response to
DNCB may highlight a receptor utilized by the hapten for
entry into the cell. CD54, part of the ICAM-1 receptor, has
its own specialized endocytic pathway [42] and although
yet to be identified in DC may be employed by mycobac-
teria to gain entry in macrophages [43]. The down-
regulation of MHC-class 1 and class II in atopic donors
may also represent a recycling pathway of both molecules.
The fact that only DNCB altered the phenotype of enriched
DC suggests that the two sensitizers may have different
recognition pathways. A possible difference has been
identified with the suggestion that DNCB preferentially
binds to cellular protein whereas TMA preferentially binds
to exogenous or serum proteins [44]. Another possibility is
that the two haptens may have multiple mechanisms of
action on DC. This may be the case for DNCB, which has
been shown to bind to a large number of intracellular
proteins by Pickard et al. [45].
In conclusion, we have demonstrated that early cyto-
kine production by DC in vitro in response to hapten
treatment may have a function in promoting or inhibiting
the level of T cell proliferation upon antigen presentation.
DC from control donors were best able to differentiate
between contact and respiratory haptens through cyto-
kine production and effects on T cell stimulation. These
results suggest that an in vitro test developed to identify
chemical haptens may be better based on DC from normal
non-atopic individuals because their cells show more
consistent reactivity to the chemical sensitizers.
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